anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a safe, inexpensive and easy means for supplementing the deficiency of female hormone (estrogen) in blood in a middle and advanced aged female in a food shape.  &lt;P&gt;SOLUTION: Steamed raw material soybeans are transported to a sterilized chamber, and Rhizopus microsporus var. oligosporus grown in pure culture is added thereto and mixed well. The mixture is inserted into a stainless vat and kept warm at 35°C for 12 h. The resultant product is taken out from an incubator, transferred to a shelf at a room temperature and left there for 24 h. The obtained product is sterilized by putting the product in an oven at 100°C for 1 h after confirming that mycelia have prevailed over the whole. The obtained soybean-fermented product is frozen and preserved. The preserved fermented product is pulverized by adding 75% ethanol in an amount of 1.8 times after thawing, and a supernatant is separated by centrifugal separation. Further a supernatant is separated by the centrifugal separation after adding 50% ethanol in an amount of 1.7 times to the precipitate, and pulverizing the added product. The supernatants obtained by the two-time centrifugal separations are mixed, and heated and concentrated until the content of the solid components becomes 20%. The liquid food having the estrogen activity is obtained by heat-sterilizing the product.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT
Process for the preparation of compositions rich in lipids or proteins from vegetable sources, the compositions so prepared and their use in cosmetics, pharmaceuticals, and foodstuffs.  The compositions are prepared by the following method: (a) a cereal flour or cereal concentrate is added to a polar solvent or mixture of polar solvents and stirred vigorously for a few hours at 30 - 80  deg C, preferably 30 - 50  deg C, in a ratio of 1: 1 - 10, and preferably 1:1 - 5, and the mixture separated to give a filtrate rich in polar and apolar lipids; (b) the filtrate is concentrated to a homogeneous orange-brown oil which is dehydrated, this oil forming the total lipidic fraction. In a separate stage (b&#39;) the delipidated filter cake from the original separation is recovered by any suitable means. The starting materials are preferably wheat, millet, or rice, the flour having a particle size that is 99% below 1,000  mu m and 44% below 450  mu m. After stage b) the lipidic fraction may be further treated with a non-polar solvent to separate the polar lipids, which are insoluble and precipitate, and these are purified. The solution is then concentrated to give an oil rich in neutral lipids. The preferred solvent for the first stage is ethanol, and the preferred solvent for the separation of polar and non-polar lipids is acetone. The total lipidic extract contains 8 - 10% of a non-lipidic fraction, 38 - 45% neutral lipids, 7 - 9% unsaponifiables, 13 - 16% phospholipids, 16 - 20% glycolipids, and 3 - 5% ceramides and glycosyl ceramides. Independent claims cover a process for making a gel rich in proteins in which a composition as described (15%) is emulsified with water, sodium hydroxide and glycerin at 50 - 60 deg C. This gel may then be used for film manufacture, for textile impregnation, or to make patches.
PROBLEM TO BE SOLVED: To obtain a liquid antacid composition not containing an antiseptic by making the composition contain calcium chloride and a pH adjusting agent. SOLUTION: This composition contains (A) 2-40 (W/V)% of calcium chloride, (B) 0.02-10 (W/V)% of a pH adjusting agent capable of keeping pH of an antacid pharmacy at &gt;=9, and an excipient, as necessary. Preferably, the composition contains 100-2,000 mg/5 ml of calcium chloride and 1-500 mg/5 ml of the pH adjusting agent. The pH of a final product is adjusted within the range of 9-12.5. As the pH adjusting agent, magnesium hydroxide, sodium carbonate, sodium carbonate dihydroxyaluminum, etc., is used. The liquid antacid composition is perorally administered to neutralize excess gastric acid, and is also useful for therapy of gastrointestinal injury such as acid maldigestion, heartburn, maldigestion, acidic stomach and regurgitant esophagitis.
PROBLEM TO BE SOLVED: To obtain a melanogenesis inhibitor excellent in bleaching effect by using a compound of specific structure represented by kuraridin. SOLUTION: This melanogenesis inhibitor is obtained by using a compound of formula I (R1 to R5 are each H, a 1-4C acyl or 1-4C alkyl; R6 is a 9-12C alkenyl having at least two C=C bonds), pref. kuraridin of formula II and/or a salt thereof. The compound of formula I is obtained by chemical synthesis such as through condensation between an acylated phenol and aldehyde or flavon&#39;s ring opening process; alternatively, being rich in, as a natural matter, plants such as Sophorae radix and Sophora flavescens. Aix, the compound can be obtained by purifying the extract from these plants. When the compound of formula I is to be used in a preparation for external use for skin, it is included pref. at 0.01-10 wt.% in the total amount of the preparation.
A multidose transdermal drug delivery assembly comprises a laminate composite having a plurality of reservoirs (7) formed therein. Unit doses with transdermal drug actives for transdermal administration are disposed in the reservoirs. Individual seals (5) enclose the drug in each of the reservoirs. The unit doses are in the form of a multiphase composition of microspheres wherein an internal phase comprises the drug actives and adjuvants surrounded by an outer phase of film-forming polysaccharides engrafted with transdermal promoters. The microspheres are distributed through a diffusable matrix for the composition. The individual seals (5), upon activation, disrupt the microspheres (8) to release the drug actives and adjuvants in the unit dose compartment (7), and the drug diffuses through the matrix to a patient&#39;s skin. A security strip (14) may be provided to prevent accidental activation of the drug.
PROBLEM TO BE SOLVED: To obtain white cerium oxide powder effective in shielding UV by firing cerium oxide powder at a specified temp. in an oxidizing atmosphere. SOLUTION: A base such as an ammonia soln. is added to an aq. cerium salt sold. to neutralize the cerium salt soln. and to deposit a precipitate. This precipitate is crystallized by heating in an autoclave and the resultant intermediate product is dehydrated if necessary and is washed and dried to form yellowish cerium oxide powder. This powder is fired at &gt;=700 deg.C, preferably &gt;=800 deg.C, especially preferably &gt;=1,000 deg.C for 2-3hr in an oxidizing atmosphere to obtain the objective white cerium oxide powder having &lt;=2.0μm average particle diameter (Stakes diameter) and a yellow index (YI) of &lt;=20 and suitable for use as a material added to water and oil paints and cosmetics for skin care, make-up, etc.
25,604. Des Houlieres, J. M. A. B., and Deschamps, E. July 12, [Convention date]. Suppositories, ovules, bougies, and pencils are moulded in thin envelopes consisting of unleavened bread which may be impregnated with paraffin, stearin, spermaceti, wax, vegetable or artificial wax, ozokerit, resin, butter, or oil. An inert powder, such as plaster, or talc, may be mixed with the material forming the unleavened bread. The envelope may be removed by breaking or moistening before use or may be left in place, in which case it is moistened with water, oil, or an antiseptic liquid. The suppositories, ovules, &amp;c. are composed of medicaments mixed with ordinary materials such as cocoa-butter, or a mixture of gelatine and glycerine. Suppositories &amp;c. moulded in envelopes of metal, cardboard, tin-foil paper, or cocoa-butter are referred to.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a method for industrially advantageously producing a compound expressed by formula [I] useful as an anticancer agent or its pharmacologically acceptable salt.  &lt;P&gt;SOLUTION: In this method for producing an indolopyrrolocarbazole derivative, a compound expressed by formula [XIII] is reacted with hydrogen gas in the presence of a rhodium compound and a metal compound. Then, the obtained compound is reacted with a compound of formula [XI] or a compound of formula [X], further reacted with a compound of formula [IX]. Fourthly, the obtained compound of formula [VIII] is cyclized. Fifthly, the obtained compound of formula [VII] is coupled with a glucose derivative of formula [VI]. Sixthly, the obtained compound is treated with a base. Seventhly, the obtained compound is reacted with a compound of formula [III]. And finally, a protecting group of the obtained compound is removed, so that the compound expressed by formula [I] is produced. A catalyst for hydrogenation reaction is used in the method.  &lt;P&gt;COPYRIGHT: (C)2004,JPO
&lt;P&gt;PROBLEM TO BE SOLVED: To allow the diagnosis history and references of a patient required for a diagnosis to be known without affecting the creation of medical records.  &lt;P&gt;SOLUTION: A observation information display section 42 for entering the observations of a doctor and an order display section 43 for entering a prescription, guidance, or the like are provided on a screen 40 for medical records of the patient. Additionally, an index display section 57 for retrieving the references to be referred to, for example, when diagnosing the patient is provided. When a switching section 57c on the index display section 57 is operated, a history display section (not shown) showing a medical examination history is displayed. As a result, the doctor can determine the medical examination history of the patient in a diagnosis. Additionally, when an index is selected on the index display section 57, keywords belonging to the index are displayed. When either keyword is selected, a reference display section 58 of an inspection result, or the like corresponding to the selected keyword is displayed on the order display section 43.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
FIELD: medicine.SUBSTANCE: invention refers to dentistry, orthopedics and orthodontics and can be used for diagnosing and correcting detected respiratory pathologies combined with a locomotor system pathology when planning orthopedic and/or orthodontic treatment. Performing general and dental history. Dental history includes patient&#39;s answers to questions on tooth sensitivity, problems with chewing, speech, jaw joints, occlusion, previous dental or orthodontic treatment, onset of head and neck cramps. Oral cavity examination is performed to obtain Brookscheker data. Epwort is determined for determination of somnolence. Patient&#39;s face is photographed with a smile, in a relaxed state, with an open mouth, with relaxed muscles with subsequent determination of aesthetic facial parameters. Aesthetic parameters of the smile are determined, including the evaluation of the combination of the tooth shape, position, size and color, their proportions and symmetry relative to each other and facial components. Locomotor system is examined by electromyography, podoscopy and fluoroscopy. Polysomnographic examination of the patient is performed. It involves a head telo-radiograph in a straight and a lateral projection, an orthopantogram, a computed tomography of a temporomandibular joint. MRI of the head is performed with subsequent processing of the obtained image by means of a computing unit and obtaining on the monitor a three-dimensional image of a patient&#39;s head containing an image of teeth and soft tissues of the oral cavity, then the obtained image is analyzed by cephalometry. If observing a pathology of respiratory organs in a combination with a pathology of the locomotor system, the orthopedic and/or orthodontic treatment is combined with osteopathic treatment. Before performing the orthopedic and/or orthodontic treatment, the desired occlusion is simulated on the virtual model of the patient&#39;s head by means of the Gamma Dental program, followed by a spinal therapy.EFFECT: method enables reducing functional problems in body operation after correction of occlusion due to complex approach to diagnosis and treatment of human and set of objective functional analysis in various fields of medicine at the stage of treatment planning.1 cl
A nucleic acid enzyme with allosteric RNA-cleaving activity on a target RNA. An expression vector containing a DNA coding for the nucleic acid enzyme. A method for producing the nucleic acid enzyme, in which an expression vector DNA containing a DNA encoding the nucleic acid enzyme is used as a template in the transcription to RNA. A pharmaceutical composition containing the nucleic acid enzyme or the expression vector containing the DNA coding for the nucleic acid enzyme as an effective component. A method for specifically cleaving target RNA by using the nucleic acid enzyme.  &lt;IMAGE&gt;
PURPOSE: A composition for preventing and treating Lysimachiae foenum-graeci Herba extract is provided to suppress differentitation and generation of osteoclast and to enhance bone density. CONSTITUTION: A pharmaceutical composition for preventing and treating bone diseases contains Lysimachiae foenum-graeci Herba extract as an active ingredient. The bone diseases are osteoporosis, osteomalacia, osteopenia, bone atrophy, fibrous dysplasia, Paget&#39;s disease, or rheumatoid arthritis. The composition is used in the form of capsule, tablet, granule, powder, or beverage. A health food for treating and relieving bone diseases contains Lysimachiae foenum-graeci Herba extract as an active ingredient. The health food is used in the form of capsule, tablet, granule, powder, or beverage.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a new mannanase, to provide a transformant of the same, and to provide a method for using the same.  &lt;P&gt;SOLUTION: A mannanase gene is cloned by Escherichia coli having a specified amino acid sequence. A transformant of the gene and a method for producing the new mannanase are provided, respectively. An enzyme preparation contains the mannanase, cellulase, protease, lipase, amylase, pectinase, xyloglucanase, or the like. A detergent composition contains the enzyme preparation. The detergent composition is used for treating fibers, waste paper, and a coffee extract, and for cleaning teeth, contact lenses, and personal goods.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
The current invention features methods for reliably and controllably separating immunoglobulin half antibodies from immunoglobulin whole antibodies, as well as purified immunoglobulin half antibody preparations and purified immunoglobulin whole antibody preparations while preserving biological activity. These dissociated half antibodies can be chromatographically separated from whole antibodies. There are four known subclasses of IgG molecules: IgG1; IgG2; IgG3; and IgG4. IgG4 molecules differ from the other IgG isotypes in that the disulfide bonds that link the two heavy chain subunits together do not always form. Due to the non-covalent interactions that hold the heavy chain subunits together, the heterogeneity of IgG4 molecules is not apparent following gel filtration of purified IgG4 protein. However, when purified IgG4 protein is separated by denaturing polyacrylamide gel electrophoresis (SDS-PAGE) under non-reducing conditions, two distinct protein species can be identified - whole antibody and &#34;half-antibodies&#34;.
Natalizumab is a safe and efficacious treatment for inflammatory and autoimmune diseases, such as multiple sclerosis, Crohn&#39;s Disease, and rheumatoid arthritis. Chain swapping between natalizumab and IgG4 molecules acts to reduce the level of bivalent natalizumab present following administration of natalizumab, and thus to lower the activity of natalizumab in the patient. Differences in IgG4 levels across patients or within a single patient across time may change the pharmacokinetic profile of natalizumab. Patients with lower levels of IgG4 may experience higher nadir levels of natalizumab during a dosing period. Monitoring IgG4 and/or bivalent natalizumab levels, and determining a dose or dosage period based on the monitoring may improve the safety and/or efficacy of natalizumab therapy. ® KIPO &amp; WIPO 2009
The present application relates to systems and methods for peritoneal dialysis exchange with a reusable energy supply unit. A system and method are provided to allow multiple patients to receive peritoneal dialysis treatment at a walk-in facility without having to keep fresh dialysis solution on their own hands. The walk-in facility enables a peritoneal dialysis prescription to be received from a patient, the prescription to be verified, an appropriate treatment to be used for the patient to be determined, an appropriate amount of an appropriate dialysis solution to be provided to the patient, and a dialysis treatment to be performed by the patient at the facility. The walk-in facility may also enable monitoring of the patient&#39;s home dialysis treatment and adjusting the patient&#39;s treatment at the facility accordingly. The facility may enable on-demand production of the solution by producing a dialysis solution from solution components according to a patient prescription. In addition, the facility may use a sorbent system to regenerate the effluent dialysis solution into fresh dialysis solution.
PURPOSE:To obtain the title composition suppressing sweating phenomena by incorporating a solid cosmetic composition such as lipstick, rough or foundation with a lanolin fatty acid and/or its ester. CONSTITUTION:The objective composition virtually preventing sweating phenomena can be obtained by incorporating (A) a lanolin fatty acid and/or its ester (in particular, as the alcohol of the ester, pref. &gt;=6C straight chain or branched saturated or unsaturated alcohol, sterol, triterpene alcohol or polyhydric alcohol; e.g. lanolin fatty acid decyl ester, lanolin fatty acid stearyl ester is pref.) in (B) a solid cosmetic composition. The present composition does not cause sweating phenomena even stored for a long period, leading to markedly improving its commodity value.
The invention belongs to the technical field of medicines, in particular to a traditional Chinese medicine composition treating heart yin depletion hyperthyroidism merged self-discipline auricular tachycardia. The traditional Chinese medicine composition is prepared from the following traditional Chinese medicines in parts by weight: 4-8 parts of caragana microphylla, 4-8 parts of Balanophora polyandra Griff, 4-8 parts of Parish&#39;s Ironweed, 4-8 parts of common triplostegia root, 4-8 parts of oriental paperbush flower, 4-8 parts of Bulbophyllum psychoon Reichb. f., 4-8 parts of Phtheirospermum tenuisectum Bur. et Franch., 4-8 parts of medical angiopteris rhizome, 4-8 parts of satyrium henryi schlecht, 4-8 parts of nutgrass flatsedge, 4-8 parts of fiveleaf akebia fruit, 4-8 parts of rattlesnake plantain, 4-8 parts of fruit of Celastrus flagellaris, 4-8 parts of ziziphora clinopodioides lam and 4-8 parts of licorice root. The traditional Chinese medicines are merged to realize effects of nourishing yin and blood, nourishing heart and tonifying deficiency, resolving hard lumps and soothing nerves. The medicine can reduce average heart rate, recover a thyroid function level, has no influence on safety index and is good in safety.
PROBLEM TO BE SOLVED: To obtain the subject composition improving the itching and dryness of skin after taking a bath, and capable of expressing a good warm touch by including a specific vanillyl alcohol alkyl ether. SOLUTION: This composition contains a vanillyl alcohol alkyl ether of the formula (R&lt;1&gt; is a 1-6C alkyl). One or more kinds of the vanillyl alcohol alkyl ethers may combinedly be added to the composition in a total amount of 0.1-10 wt.%, preferably 0.5-2 wt.%, based on the whole composition. The amount of the composition for each use is preferably determined so that the vanillyl alcohol alkyl ether is contained in bath warm water in an amount of 0.1-500 ppm, especially 0.2-400 ppm. The composition preferably further contains an inorganic salt (e.g. sodium chloride, sodium bicarbonate), an oily component (e.g. an oil or fat, a wax, a hydrocarbon) and the like.
PURPOSE:To provide a medicine for improvement of airway obstruction, containing a human polymorphonuclear leukocyte elastase inhibitory protein (SLPI) as the active component. CONSTITUTION:This madicine contains a polypeptide [e.g. (Arg&lt;58&gt;-Ala&lt;107&gt;)SLPI] having an amino acid sequence represented by the table, another polypeptide having the amino acid sequence or another polypeptide having an amino acid sequence biologically equal thereto as the active component. Preparation is possible in the form of an oral administration type and a parenteral administration type such as an intravenous injection type, a subcutaneous type, an intramuscular type, a dermal type, an aspiration type or an intrarectal type. The dosage of the polypeptide is 1 to 1000mg/time and administration is one to three times a day. This medicine is effective for, e.g. airway obstruction accompanying a respiratory disease in which the number of leukocytes in sputum or a bronchovesicule-wash liquid is increased, acute or chronic obstructive diseases caused by a neutrophil-or acidphil-derived protease or acute or chronic obstructive lung diseases caused by airway hypersensitive sthenia.
PROBLEM TO BE SOLVED: To suppress the radical generation when zinc oxide absorbs UV rays by treating zinc oxide particulates in a phosphoric acid solution to allow a phosphoric acid group to exist as zinc phosphate on particulate surfaces. SOLUTION: The zinc oxide particulates of &lt;=1 μm in major axis are immersed in the dilute solution of phosphoric acid and are heated to about 80 deg.C, following which the solution is stirred and held for 1 to 5 hours. The solution is baked for 10 to 24 hours at 250 to 350 deg.C after filtering and washing with water, by which the zinc oxide particulates coated with the phosphoric acid group as zinc phosphate on the particulate surfaces at a thickness of 0.003 to 0.1 μm are obtained. The radical generation is suppressed without the impairment of the UV absorption characteristic and optical effect of the zinc oxide by this treatment. The surface treated zinc oxide particulates are preferably applied to materials used under exposure of light as cosmetics. The applications to cosmetics for sun care and makeup cosmetics, such as foundation, are preferable.  The particulates are also adequate for use with persons having the sensitive skin.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a DNA encoding a frazzled protein family including WA628, a method for producing the DNA and use thereof.  &lt;P&gt;SOLUTION: The protein may be used in inducing the expression of a factor in tissues and organs and/or the differentiation of tissues and organs, particularly, may be used in inducing the formation, growth, differentiation, proliferation and/or maintenance of various tissues and organs. The protein is useful in the treatment of various disorders associated with defects in cellular formation, growth, differentiation, proliferation and/or maintenance of a variety of tissues and organs including, for example, brain, lung, pancreas, liver, spleen, kidney, small intestine and/or other tissues and organs. The protein is also useful for augmenting the activity of other tissue regenerating and differentiation factors. Especially, the protein is useful for modulating hematopoietic tissue and modulating the development of gut, brain and muscle tissues.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT